pI: 6.8898 |
Length (AA): 149 |
MW (Da): 17521 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 3 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
10 | 141 | 1h2t (Z) | 10 | 150 | 63.00 | 0 | 1 | 1.56271 | -0.17 |
38 | 109 | 1h6k (X) | 38 | 118 | 65.00 | 0 | 1 | 1.13692 | -0.06 |
65 | 106 | 2ghp (A) | 243 | 286 | 24.00 | 0 | 0.09 | 0.393679 | 0.9 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_127988)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G44200 | nuclear cap-binding protein subunit 20 |
Babesia bovis | BBOV_IV008110 | nuclear cap-binding protein, putative |
Brugia malayi | Bm1_02935 | nuclear cap binding protein subunit 2 |
Candida albicans | CaO19.763 | Nuclear mRNA cap binding protein, spliceosome |
Candida albicans | CaO19.8383 | Nuclear mRNA cap binding protein, spliceosome |
Caenorhabditis elegans | CELE_F26A3.2 | Protein NCBP-2, isoform C |
Cryptosporidium hominis | Chro.60207 | nuclear cap-binding protein |
Cryptosporidium parvum | cgd6_1700 | RRM domain containing protein |
Dictyostelium discoideum | DDB_G0287197 | RNA recognition motif-containing protein RRM |
Drosophila melanogaster | Dmel_CG12357 | cap binding protein 20 |
Echinococcus granulosus | EgrG_000389400 | Nuclear cap binding protein subunit 2 |
Entamoeba histolytica | EHI_156270 | RNA recognition motif domain containing protein |
Echinococcus multilocularis | EmuJ_000389400 | Nuclear cap binding protein subunit 2 |
Leishmania braziliensis | LbrM.30.0620 | nuclear cap binding protein, putative |
Leishmania donovani | LdBPK_300560.1 | nuclear cap binding protein, putative |
Leishmania infantum | LinJ.30.0560 | nuclear cap binding protein, putative |
Leishmania major | LmjF.30.0540 | nuclear cap binding protein, putative |
Leishmania mexicana | LmxM.29.0540 | nuclear cap binding protein, putative |
Loa Loa (eye worm) | LOAG_03270 | nuclear cap binding protein subunit 2 |
Mus musculus | ENSMUSG00000022774 | nuclear cap binding protein subunit 2 |
Neospora caninum | NCLIV_041810 | nuclear cap-binding protein, putative |
Oryza sativa | 4329963 | Os02g0612300 |
Plasmodium berghei | PBANKA_0717500 | nuclear cap-binding protein subunit 2, putative |
Plasmodium falciparum | PF3D7_0415500 | nuclear cap-binding protein subunit 2, putative |
Plasmodium knowlesi | PKNH_0507100 | nuclear cap-binding protein subunit 2, putative |
Plasmodium vivax | PVX_089730 | nuclear cap-binding protein, putative |
Plasmodium yoelii | PY02814 | RNA recognition motif, putative |
Saccharomyces cerevisiae | YPL178W | Cbc2p |
Schistosoma japonicum | Sjp_0201400 | Nuclear cap-binding protein subunit 2, putative |
Schistosoma mansoni | Smp_166430 | nuclear cap binding protein |
Schmidtea mediterranea | mk4.010828.01 | Nuclear cap-binding protein subunit 2 |
Schmidtea mediterranea | mk4.003895.02 | Nuclear cap-binding protein subunit 2 |
Trypanosoma brucei gambiense | Tbg972.6.1690 | nuclear cap binding protein, putative |
Trypanosoma brucei | Tb927.6.1970 | nuclear cap binding protein, putative |
Trypanosoma congolense | TcIL3000_0_33890 | nuclear cap binding protein, putative |
Trypanosoma cruzi | TcCLB.504071.80 | nuclear cap binding protein, putative |
Toxoplasma gondii | TGME49_289560 | RNA recognition motif-containing protein |
Theileria parva | TP01_0963 | nuclear cap-binding protein, putative |
Trichomonas vaginalis | TVAG_345370 | 20 kD nuclear cap binding protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.6.1970 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (3 days) | alsford |
Tb927.6.1970 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.6.1970 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.6.1970 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
CELE_F26A3.2 | Caenorhabditis elegans | embryonic lethal | wormbase |
CELE_F26A3.2 | Caenorhabditis elegans | larval arrest | wormbase |
CELE_F26A3.2 | Caenorhabditis elegans | slow growth | wormbase |
CELE_F26A3.2 | Caenorhabditis elegans | sterile | wormbase |
PBANKA_0717500 | Plasmodium berghei | Dispensable | plasmo |
TGME49_289560 | Toxoplasma gondii | Probably essential | sidik |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.